SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Momenta Pharmaceuticals Inc.
An SI Board Since March 2004
Posts SubjectMarks Bans Symbol
3027 64 0 MNTA
Emcee:  michael_f_murphy Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2952Teva just lost the appeal wrt to process patent that protected Copaxone until 2tuck-7/26/2013
2951The Teva-Lonza FoB collaboration was effectively dead already—please see siliconDewDiligence_on_SI-7/25/2013
2950Jerusalem and Basel, Switzerland, July 25, 2013 – Teva Pharmaceutical Industriesnigel bates-7/25/2013
2949CAMBRIDGE, Mass., June 25, 2013 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Incnigel bates-7/1/2013
2948NVS reports $85M of 4Q12 Lovenox sales, up from $34M in 3Q12: siliconinvestor.DewDiligence_on_SI-1/23/2013
2947CAFC denies petition for en banc hearing, so it's off to US Supreme Court fotuck-11/20/2012
2946NVS reported unexpectedly weak 3Q12 Lovenox sales about a month ago, and MNTA’s DewDiligence_on_SI-11/17/2012
2945Why has the stock been down so much the past month and a half? I have not lookeBiotech Jim-11/16/2012
2944Why has the stock been down so much the past month and a half? I have not lookeBiotech Jim-11/16/2012
2943MNTA ‘ReadMeFirst’ updated again for favorable comments by CFO re Lovenox run raDewDiligence_on_SI-11/16/2012
2942MNTA ‘ReadMeFirst’ updated: <i>timing of MNTA’s FoB payments from BAX; NVDewDiligence_on_SI-11/14/2012
2941Novartis sales of mEnox this q = $34 million, while Watson reports much higher ttuck-10/25/2012
2940Karst updates as rehearing petitions have been filed: http:/// (thanks to Dew tuck-10/24/2012
2939Kurt Karst summarizes, with less opinionating than Guttag (as is his custom): ftuck-8/8/2012
2938Fine article - thanks. I am surprised at the outcome so far. Hopefully en bancIRWIN JAMES FRANKEL-8/7/2012
2937An IP lawyer makes the case that the Momenta/Amphastar decision is overly expanstuck18/7/2012
2936MNTA ‘ReadMeFirst’ updated: <i>revised table of biotech buyouts resultiDewDiligence_on_SI-8/6/2012
2935seems to me they have a good position for en banc, but either way, still more demopgcw-8/6/2012
2934MNTA <i>ReadMeFirst</i> updated with Appellate Court ruling and otheDewDiligence_on_SI-8/5/2012
2933>>CAMBRIDGE, Mass., Aug. 3, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticatuck-8/5/2012
2932MNTA <i>ReadMeFirst</i> updated: siliconinvestor.com There are toDewDiligence_on_SI-8/1/2012
2931bloomberg.com Could Momenta be chasing a futile dream against Teva--as pointed Arthur Radley-7/17/2012
2930M402 => should we be watching Curis' GDC-0449 in pancreatic cancer? In ttuck17/3/2012
2929cs: Teva Wins Copaxone Patent Case, Removing a Major Overhang Bottom line. Folmopgcw-6/25/2012
2928Clearing up some confusion about FDA approval of MNTA’s Copaxone ANDA: siliconiDewDiligence_on_SI-6/23/2012
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News